Junshi Biosciences Announces Inclusion of Toripalimab in The China National Reimbursement Drug List

    NEXT STORY
    Changes to the Nomination Committee for Immunicum AB (publ)
    PREV STORY
    Zai Lab Announces Inclusion of ZEJULA® (Niraparib) in China’s National Reimbursement Drug List
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Ascendis Pharma A/S Announces Participation in 38th Annual J.P. Morgan Healthcare Conference

    author_avatar
    NASDAQ Market News

    Immunovaccine Chief Medical Officer Dr. Gabriela Rosu to Present at the Oncology Meeting Innovations (OMI) Annual Summit on Hematologic Malignancies

    HALIFAX, Nova Scotia, March 08, 2018 (GLOBE NEWSWIRE) -- Immunovaccine Inc. (TSX:IMV) (OTCQX:IMMVF), a ...

    author_avatar
    NASDAQ Market News

    Profound Medical Announces Positive Topline Results from TACT Pivotal Clinical Trial of TULSA-PRO® in Patients with Prostate Cancer

    author_avatar
    NASDAQ Market News